Want to create an interactive transcript for this episode?
Podcast: Share Talk LTD
Episode: Tim McCarthy, Chief Executive Officer of ImmuPharma PLC talks to Zak Mir
Description: Zak Mir talks to Tim McCarthy, CEO of Immupharma, the speciality biopharmaceutical company that discovers and develops peptide-based therapeutics, announcing the filing of a groundbreaking new patent application for its lead asset, P140, the world’s first “Immunormalizer.”The three discoveries that reset the strategy
Under-dosing: The team concluded the dose used in the Phase III trial was far too low — roughly 10 to 15 times lower than the dose they now believe is required to achieve the intended biological effect.
Steroid confounding: Standard-of-care steroids given to patients in the trial suppress the immune system and masked P140’s effect...